## NATALIA LAPTEVA

| | Title| Associate Professor  
---|---  
Institution| Baylor College of Medicine  
Department| Department of Pathology & Immunology  
Address| 1102 BATES  
Houston, TX 77030  
  
Email|
![](https://profiles.viictr.org/profile/modules/CustomViewPersonGeneralInfo/EmailHandler.ashx?msg=OKcx8XHCNorVRIzgrn7GPw%3d%3d&rnd=79289e80-4feb-453f-a314-9decd3af2d38)  
vCard| [Download
vCard](https://profiles.viictr.org/profile/modules/CustomViewPersonGeneralInfo/vcard.aspx?subject=269143)  
  

Other Positions| Title| Associate Professor  
---|---  
Institution| Baylor College of Medicine  
Department| Center for Cell & Gene Therapy  
Division| Center for Cell & Gene Therapy  
  
  
  
  
![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
Bibliographic  

![Collapse](https://profiles.viictr.org/Profile/Modules/PropertyList/images/minusSign.gif)
selected publications

Publications listed below are automatically derived from MEDLINE/PubMed and
other sources, which might result in incorrect or missing publications.
Faculty can
[login](https://profiles.viictr.org/loginOptions.aspx?pin=send&method=login&edit=true)
to make corrections and additions.

Newest | Oldest | Most Cited | Most Discussed | Timeline | Field Summary | Plain Text

PMC Citations indicate the number of times the publication was cited by
articles in PubMed Central, and the Altmetric score represents citations in
news articles and social media. (Note that publications are often cited in
additional ways that are not shown here.) Fields are based on how the National
Library of Medicine (NLM) classifies the publication's journal and might not
represent the specific topic of the publication. Translation tags are based on
the publication type and the MeSH terms NLM assigns to the publication. Some
publications (especially newer ones and publications not in PubMed) might not
yet be assigned Field or Translation tags.) Click a Field or Translation tag
to filter the publications.

  1. Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, **Lapteva N** , [Mei Z](https://profiles.viictr.org/profile/267093), Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, [Scherer L](https://profiles.viictr.org/profile/22016570), Shekar M, [Baxter P](https://profiles.viictr.org/profile/265524), Wang T, [Grilley B](https://profiles.viictr.org/profile/266987), [Moeller K](https://profiles.viictr.org/profile/51898388), Hicks J, [Roy A](https://profiles.viictr.org/profile/268647), [Anastas J](https://profiles.viictr.org/profile/33092477), Malbari F, Aldave G, [Chintagumpala M](https://profiles.viictr.org/profile/268049), [Blaney S](https://profiles.viictr.org/profile/268174), [Parsons DW](https://profiles.viictr.org/profile/265886), [Brenner MK](https://profiles.viictr.org/profile/268200), [Heslop HE](https://profiles.viictr.org/profile/269811), [Rooney CM](https://profiles.viictr.org/profile/268355), [Omer B](https://profiles.viictr.org/profile/3009902). Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 May 21; JCO2302019. PMID: [38771986](//www.ncbi.nlm.nih.gov/pubmed/38771986).

Citations:  Fields:

Neo Neoplasms

  2. [Hegde M](https://profiles.viictr.org/profile/270076), [Navai S](https://profiles.viictr.org/profile/6714386), DeRenzo C, [Joseph SK](https://profiles.viictr.org/profile/31879883), Sanber K, Wu M, [Gad AZ](https://profiles.viictr.org/profile/24845005), Janeway KA, Campbell M, [Mullikin D](https://profiles.viictr.org/profile/17411489), Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, [Grilley B](https://profiles.viictr.org/profile/266987), **Lapteva N** , [Gee A](https://profiles.viictr.org/profile/268378), Dotti G, Bao R, Salem AH, Wang T, [Brenner MK](https://profiles.viictr.org/profile/268200), [Heslop HE](https://profiles.viictr.org/profile/269811), Wels WS, Hicks MJ, [Gottschalk S](https://profiles.viictr.org/profile/270181), [Ahmed N](https://profiles.viictr.org/profile/268944). Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894. PMID: [38658775](//www.ncbi.nlm.nih.gov/pubmed/38658775).

Citations:  Fields:

Neo Neoplasms

Translation:HumansCellsCTClinical Trials

  3. Hill LC, [Rouce RH](https://profiles.viictr.org/profile/3010108), Wu MJ, Wang T, Ma R, Zhang H, Mehta B, **Lapteva N** , [Mei Z](https://profiles.viictr.org/profile/267093), Smith TS, Yang L, Srinivasan M, [Burkhardt PM](https://profiles.viictr.org/profile/31454204), [Ramos CA](https://profiles.viictr.org/profile/267038), [Lulla P](https://profiles.viictr.org/profile/3010220), Arredondo M, [Grilley B](https://profiles.viictr.org/profile/266987), [Heslop HE](https://profiles.viictr.org/profile/269811), [Brenner MK](https://profiles.viictr.org/profile/268200), [Mamonkin M](https://profiles.viictr.org/profile/1826306). Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241. PMID: [38145560](//www.ncbi.nlm.nih.gov/pubmed/38145560); PMCID: [PMC10997912](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10997912).

Citations:  Fields:

Hem Hematology

Translation:HumansCells

  4. [Vasileiou S](https://profiles.viictr.org/profile/22016531), Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, [Lulla S](https://profiles.viictr.org/profile/34811365), Mooney K, **Lapteva N** , [Grilley BJ](https://profiles.viictr.org/profile/266987), [Heslop HE](https://profiles.viictr.org/profile/269811), [Rooney CM](https://profiles.viictr.org/profile/268355), [Brenner MK](https://profiles.viictr.org/profile/268200), Eagar TN, [Carrum G](https://profiles.viictr.org/profile/269657), Grimes KA, [Leen AM](https://profiles.viictr.org/profile/268626), [Lulla P](https://profiles.viictr.org/profile/3010220). Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850. PMID: [36373249](//www.ncbi.nlm.nih.gov/pubmed/36373249); PMCID: [PMC10316279](//www.ncbi.nlm.nih.gov/pmc/articles/PMC10316279).

Citations:
[6](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/36373249/citedby/) Fields:

Hem Hematology

Translation:HumansCellsCTClinical Trials

  5. [Hoyos V](https://profiles.viictr.org/profile/23479202), [Vasileiou S](https://profiles.viictr.org/profile/22016531), Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, [Lulla S](https://profiles.viictr.org/profile/34811365), Robertson C, Foreman C, Wang T, Bulsara S, **Lapteva N** , [Grilley B](https://profiles.viictr.org/profile/266987), Ellis M, Osborne CK, Coscio A, [Nangia J](https://profiles.viictr.org/profile/266130), [Heslop HE](https://profiles.viictr.org/profile/269811), [Rooney CM](https://profiles.viictr.org/profile/268355), Vera JF, [Lulla P](https://profiles.viictr.org/profile/3010220), [Rimawi M](https://profiles.viictr.org/profile/269416), [Leen AM](https://profiles.viictr.org/profile/268626). Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: [35860837](//www.ncbi.nlm.nih.gov/pubmed/35860837); PMCID: [PMC9290161](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9290161).

Citations:

  6. [Steffin DHM](https://profiles.viictr.org/profile/14348352), Muhsen IN, Hill LC, [Ramos CA](https://profiles.viictr.org/profile/267038), [Ahmed N](https://profiles.viictr.org/profile/268944), [Hegde M](https://profiles.viictr.org/profile/270076), Wang T, Wu M, [Gottschalk S](https://profiles.viictr.org/profile/270181), [Whittle SB](https://profiles.viictr.org/profile/3009971), [Lulla PD](https://profiles.viictr.org/profile/3010220), [Mamonkin M](https://profiles.viictr.org/profile/1826306), [Omer B](https://profiles.viictr.org/profile/3009902), [Rouce RH](https://profiles.viictr.org/profile/3010108), [Heczey A](https://profiles.viictr.org/profile/268789), [Metelitsa LS](https://profiles.viictr.org/profile/266187), [Grilley BJ](https://profiles.viictr.org/profile/266987), Robertson C, Torrano V, **Lapteva N** , [Gee AP](https://profiles.viictr.org/profile/268378), [Rooney CM](https://profiles.viictr.org/profile/268355), [Brenner MK](https://profiles.viictr.org/profile/268200), [Heslop HE](https://profiles.viictr.org/profile/269811). Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: [35325065](//www.ncbi.nlm.nih.gov/pubmed/35325065); PMCID: [PMC9346960](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9346960).

Citations:  Fields:

Hem Hematology

Translation:HumansCells

  7. Naik S, [Vasileiou S](https://profiles.viictr.org/profile/22016531), Tzannou I, Kuvalekar M, Watanabe A, Robertson C, **Lapteva N** , Tao W, Wu M, [Grilley B](https://profiles.viictr.org/profile/266987), [Carrum G](https://profiles.viictr.org/profile/269657), [Kamble RT](https://profiles.viictr.org/profile/265557), Hill L, [Krance RA](https://profiles.viictr.org/profile/268199), [Martinez C](https://profiles.viictr.org/profile/265827), Tewari P, [Omer B](https://profiles.viictr.org/profile/3009902), [Gottschalk S](https://profiles.viictr.org/profile/270181), [Heslop HE](https://profiles.viictr.org/profile/269811), Brenner MK, [Rooney CM](https://profiles.viictr.org/profile/268355), Vera JF, [Leen AM](https://profiles.viictr.org/profile/268626), [Lulla PD](https://profiles.viictr.org/profile/3010220). Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: [35134127](//www.ncbi.nlm.nih.gov/pubmed/35134127); PMCID: [PMC9053698](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9053698).

Citations:
[1](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35134127/citedby/) Fields:

Hem Hematology

Translation:Humans

  8. Ibenana L, Anderson R, [Gee A](https://profiles.viictr.org/profile/268378), Gilbert M, Cox C, Hare JM, Brooks A, Kelley L, Khan A, **Lapteva N** , Orozco A, Styers D, Sumstad D, Ugochi I, McKenna DH. Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study. Cytotherapy. 2022 07; 24(7):691-698. PMID: [35279374](//www.ncbi.nlm.nih.gov/pubmed/35279374); PMCID: [PMC9232931](//www.ncbi.nlm.nih.gov/pmc/articles/PMC9232931).

Citations:  Fields:

Cel Cell BiologyThe Therapeutics

Translation:Cells

  9. **Lapteva N** , Gilbert M, Diaconu I, [Rollins LA](https://profiles.viictr.org/profile/28998998), Al-Sabbagh M, Naik S, [Krance RA](https://profiles.viictr.org/profile/268199), Tripic T, Hiregange M, Raghavan D, Dakhova O, [Rouce RH](https://profiles.viictr.org/profile/3010108), Liu H, [Omer B](https://profiles.viictr.org/profile/3009902), Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, [Gee AP](https://profiles.viictr.org/profile/268378), [Ramos CA](https://profiles.viictr.org/profile/267038), [Heslop HE](https://profiles.viictr.org/profile/269811), [Brenner MK](https://profiles.viictr.org/profile/268200), [Rooney CM](https://profiles.viictr.org/profile/268355). T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: [31558475](//www.ncbi.nlm.nih.gov/pubmed/31558475); PMCID: [PMC7062259](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7062259).

Citations:
[13](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31558475/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  10. [Parihar R](https://profiles.viictr.org/profile/3009684), [Rivas C](https://profiles.viictr.org/profile/31189484), Huynh M, [Omer B](https://profiles.viictr.org/profile/3009902), **Lapteva N** , [Metelitsa LS](https://profiles.viictr.org/profile/266187), [Gottschalk SM](https://profiles.viictr.org/profile/270181), [Rooney CM](https://profiles.viictr.org/profile/268355). NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375. PMID: [30651290](//www.ncbi.nlm.nih.gov/pubmed/30651290); PMCID: [PMC7906796](//www.ncbi.nlm.nih.gov/pmc/articles/PMC7906796).

Citations:
[83](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30651290/citedby/) Fields:

All Allergy and ImmunologyNeo Neoplasms

Translation:HumansAnimalsCells

  11. [Omer B](https://profiles.viictr.org/profile/3009902), Castillo PA, Tashiro H, Shum T, Huynh MTA, [Cardenas M](https://profiles.viictr.org/profile/31194423), Tanaka M, Lewis A, Sauer T, [Parihar R](https://profiles.viictr.org/profile/3009684), **Lapteva N** , Schmueck-Henneresse M, Mukherjee M, [Gottschalk S](https://profiles.viictr.org/profile/270181), [Rooney CM](https://profiles.viictr.org/profile/268355). Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343. PMID: [30619856](//www.ncbi.nlm.nih.gov/pubmed/30619856); PMCID: [PMC6297364](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6297364).

Citations:
[3](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30619856/citedby/)

  12. Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, **Lapteva N** , [Mei Z](https://profiles.viictr.org/profile/267093), Butterfield LH, [Rooney CM](https://profiles.viictr.org/profile/268355), Whiteside TL. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232. PMID: [28864289](//www.ncbi.nlm.nih.gov/pubmed/28864289).

Citations:
[66](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28864289/citedby/) Fields:

Cel Cell BiologyThe Therapeutics

Translation:HumansCellsCTClinical Trials

  13. [Omer B](https://profiles.viictr.org/profile/3009902), Shum T, Tashiro H, [Mamonkin M](https://profiles.viictr.org/profile/1826306), **Lapteva N** , Sharma S, [Rollins L](https://profiles.viictr.org/profile/28998998), Dotti G, [Rooney CM](https://profiles.viictr.org/profile/268355), Schmueck-Henneresse M, Reinke P, Volk HD. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362. PMID: [28550199](//www.ncbi.nlm.nih.gov/pubmed/28550199); PMCID: [PMC5536854](//www.ncbi.nlm.nih.gov/pmc/articles/PMC5536854).

Citations:
[22](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28550199/citedby/) Fields:

All Allergy and Immunology

Translation:HumansCells

  14. **Lapteva N** , [Parihar R](https://profiles.viictr.org/profile/3009684), [Rollins LA](https://profiles.viictr.org/profile/28998998), [Gee AP](https://profiles.viictr.org/profile/268378), [Rooney CM](https://profiles.viictr.org/profile/268355). Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202. PMID: [27177667](//www.ncbi.nlm.nih.gov/pubmed/27177667).

Citations:
[8](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27177667/citedby/) Fields:

Mol Molecular Biology

Translation:HumansCells

  15. Sun J, Huye LE, **Lapteva N** , [Mamonkin M](https://profiles.viictr.org/profile/1826306), Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, [Omer B](https://profiles.viictr.org/profile/3009902), [Rollins LA](https://profiles.viictr.org/profile/28998998), [Leen AM](https://profiles.viictr.org/profile/268626), Vera JF, Dotti G, [Gee AP](https://profiles.viictr.org/profile/268378), [Brenner MK](https://profiles.viictr.org/profile/268200), Myers DG, [Rooney CM](https://profiles.viictr.org/profile/268355). Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5. PMID: [25734008](//www.ncbi.nlm.nih.gov/pubmed/25734008); PMCID: [PMC4346112](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4346112).

Citations:
[17](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25734008/citedby/) Fields:

Neo NeoplasmsThe Therapeutics

  16. **Lapteva N** , Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, [Khan J](https://profiles.viictr.org/profile/51399074), Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, [Gee A](https://profiles.viictr.org/profile/268378), Cottler-Fox M, [Rooney C](https://profiles.viictr.org/profile/268355), Barlogie B, van Rhee F, Szmania S. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: [25415285](//www.ncbi.nlm.nih.gov/pubmed/25415285); PMCID: [PMC4352951](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4352951).

Citations:
[79](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25415285/citedby/) Fields:

All Allergy and ImmunologyNeo NeoplasmsThe Therapeutics

Translation:HumansCellsCTClinical Trials

  17. Miller JS, [Rooney CM](https://profiles.viictr.org/profile/268355), Curtsinger J, McElmurry R, McCullar V, Verneris MR, **Lapteva N** , McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: [24816582](//www.ncbi.nlm.nih.gov/pubmed/24816582); PMCID: [PMC4099265](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4099265).

Citations:
[40](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24816582/citedby/) Fields:

Hem HematologyTra Transplantation

Translation:HumansAnimalsCells

  18. Ando J, [Leen AM](https://profiles.viictr.org/profile/268626), Ennamuri S, **Lapteva N** , Vera JF, Min-Venditti A, Mims MP, [Heslop HE](https://profiles.viictr.org/profile/269811), Bollard CM, [Gottschalk S](https://profiles.viictr.org/profile/270181), [Rooney CM](https://profiles.viictr.org/profile/268355), Ngo MC. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: [24714353](//www.ncbi.nlm.nih.gov/pubmed/24714353); PMCID: [PMC4133102](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4133102).

Citations:
[28](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24714353/citedby/) Fields:

All Allergy and ImmunologyNeo NeoplasmsThe Therapeutics

Translation:HumansCells

  19. **Lapteva N** , Szmania SM, van Rhee F, [Rooney CM](https://profiles.viictr.org/profile/268355). Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32. PMID: [24941378](//www.ncbi.nlm.nih.gov/pubmed/24941378); PMCID: [PMC4095851](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4095851).

Citations:
[22](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24941378/citedby/) Fields:

Neo Neoplasms

Translation:HumansCells

  20. **Lapteva N** , Durett AG, Sun J, [Rollins LA](https://profiles.viictr.org/profile/28998998), Huye LL, Fang J, Dandekar V, [Mei Z](https://profiles.viictr.org/profile/267093), Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, [Gee AP](https://profiles.viictr.org/profile/268378), [Rooney CM](https://profiles.viictr.org/profile/268355). Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: [22900959](//www.ncbi.nlm.nih.gov/pubmed/22900959); PMCID: [PMC4787300](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4787300).

Citations:
[91](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22900959/citedby/) Fields:

Cel Cell BiologyThe Therapeutics

Translation:HumansCells

  21. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, **Lapteva N** , Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314. PMID: [22004414](//www.ncbi.nlm.nih.gov/pubmed/22004414); PMCID: [PMC3198747](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3198747).

Citations:
[48](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22004414/citedby/) Fields:

Bio BiochemistryDru Drug TherapyMol Molecular Biology

Translation:HumansCells

  22. **Lapteva N** , Vera JF. Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int. 2011; 2011:434392. PMID: [21915183](//www.ncbi.nlm.nih.gov/pubmed/21915183); PMCID: [PMC3170896](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3170896).

Citations:
[8](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21915183/citedby/)

  23. Chiou SH, Shahi P, Wagner RT, Hu H, **Lapteva N** , Seethammagari M, [Sun SC](https://profiles.viictr.org/profile/12583869), Levitt JM, Spencer DM. The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep. 2011 Sep 01; 12(9):971-9. PMID: [21799517](//www.ncbi.nlm.nih.gov/pubmed/21799517); PMCID: [PMC3166462](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3166462).

Citations:
[8](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21799517/citedby/) Fields:

Mol Molecular Biology

Translation:AnimalsCells

  24. Narayanan P, **Lapteva N** , Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34. PMID: [21383499](//www.ncbi.nlm.nih.gov/pubmed/21383499); PMCID: [PMC3069772](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3069772).

Citations:
[31](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21383499/citedby/) Fields:

Med Medicine (General)

Translation:HumansAnimalsCells

  25. Ramachandran IR, Song W, **Lapteva N** , Seethammagari M, Slawin KM, Spencer DM, Levitt JM. The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol. 2011 Apr 01; 186(7):3934-45. PMID: [21357539](//www.ncbi.nlm.nih.gov/pubmed/21357539).

Citations:
[22](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21357539/citedby/) Fields:

All Allergy and Immunology

Translation:HumansAnimalsCells

  26. **Lapteva N** , Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010 May; 10(5):725-33. PMID: [20233026](//www.ncbi.nlm.nih.gov/pubmed/20233026).

Citations:
[38](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20233026/citedby/) Fields:

Bio BiologyThe Therapeutics

Translation:HumansAnimals

  27. **Lapteva N**. Enhanced migration of human dendritic cells expressing inducible CD40. Methods Mol Biol. 2010; 651:79-87. PMID: [20686961](//www.ncbi.nlm.nih.gov/pubmed/20686961).

Citations:  Fields:

Mol Molecular Biology

Translation:HumansCells

  28. **Lapteva N** , Aldrich M, [Rollins L](https://profiles.viictr.org/profile/28998998), Ren W, Goltsova T, Chen SY, Huang XF. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009 Sep; 17(9):1626-36. PMID: [19532135](//www.ncbi.nlm.nih.gov/pubmed/19532135); PMCID: [PMC2835257](//www.ncbi.nlm.nih.gov/pmc/articles/PMC2835257).

Citations:
[20](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19532135/citedby/) Fields:

Mol Molecular BiologyThe Therapeutics

Translation:HumansAnimalsCells

  29. **Lapteva N** , Aldrich M, Weksberg D, [Rollins L](https://profiles.viictr.org/profile/28998998), Goltsova T, Chen SY, Huang XF. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56. PMID: [19238013](//www.ncbi.nlm.nih.gov/pubmed/19238013); PMCID: [PMC4146345](//www.ncbi.nlm.nih.gov/pmc/articles/PMC4146345).

Citations:
[42](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19238013/citedby/) Fields:

All Allergy and ImmunologyNeo NeoplasmsThe Therapeutics

Translation:AnimalsCells

  30. **Lapteva N** , Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 01; 67(21):10528-37. PMID: [17974997](//www.ncbi.nlm.nih.gov/pubmed/17974997).

Citations:
[25](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/17974997/citedby/) Fields:

Neo Neoplasms

Translation:HumansAnimalsCells

  31. [Park D](https://profiles.viictr.org/profile/3939890), **Lapteva N** , Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006 Dec; 24(12):1581-90. PMID: [17143278](//www.ncbi.nlm.nih.gov/pubmed/17143278).

Citations:
[46](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/17143278/citedby/) Fields:

Bio Biotechnology

Translation:HumansAnimalsCells

  32. **Lapteva N** , Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005 Jan; 12(1):84-9. PMID: [15472715](//www.ncbi.nlm.nih.gov/pubmed/15472715).

Citations:
[64](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/15472715/citedby/) Fields:

Gen GeneticsNeo NeoplasmsThe Therapeutics

Translation:HumansAnimalsCells

This graph shows the total number of publications by year. To see the data as
text, click here.

![Bar chart showing 32 publications over 16 distinct years, with a maximum of
5 publications in
2011](//chart.googleapis.com/chart?chs=595x100&chf=bg,s,ffffff|c,s,ffffff&chxt=x,y&chxl=0:|'94||'96||'98||'00||'02||'04||'06||'08||'10||'12||'14||'16||'18||'20||'22||'24|1:|0|5&cht=bvs&chd=t:0,0,0,0,0,0,0,0,0,0,0,20,20,20,0,40,40,100,20,0,60,40,20,40,20,40,0,0,80,20,60&chdl=Publications&chco=80B1D3&chbh=10)

This graph shows the total number of publications by year. To return to the
graph, click here.

Year| Publications  
---|---  
2005| 1  
2006| 1  
2007| 1  
2009| 2  
2010| 2  
2011| 5  
2012| 1  
2014| 3  
2015| 2  
2016| 1  
2017| 2  
2018| 1  
2019| 2  
2022| 4  
2023| 1  
2024| 3  
  
This graph shows the number and percent of publications by field. Fields are
based on how the National Library of Medicine (NLM) classifies the
publications' journals and might not represent the specific topics of the
publications. Note that an individual publication can be assigned to more than
one field. As a result, the publication counts in this graph might add up to
more than the number of publications the person has written. To see the data
as text, click here.

This graph shows the number and percent of publications by field. Fields are
based on how the National Library of Medicine (NLM) classifies the
publications' journals and might not represent the specific topics of the
publications. Note that an individual publication can be assigned to more than
one field. As a result, the publication counts in this graph might add up to
more than the number of publications the person has written. To see the data
as text, click here.

Start with: newest oldest Include: line numbers double spacing all authors
publication IDs

LAPTEVA's Networks

Click the

Explore

buttons for more information and interactive visualizations!

Concepts (187)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

Derived automatically from this person's publications.

  * [Killer Cells, Natural](https://profiles.viictr.org/profile/261504)
  * [Immunotherapy, Adoptive](https://profiles.viictr.org/profile/250092)
  * [Dendritic Cells](https://profiles.viictr.org/profile/246816)
  * [CD40 Antigens](https://profiles.viictr.org/profile/245960)
  * [Chemokine CCL5](https://profiles.viictr.org/profile/248606)

[Explore](https://profiles.viictr.org/profile/269143/198)

_

Co-Authors (48)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People in Profiles who have published with this person.

  * [ROONEY, CLIONA](https://profiles.viictr.org/profile/268355)
  * [OMER, BILAL](https://profiles.viictr.org/profile/3009902)
  * [HESLOP, HELEN](https://profiles.viictr.org/profile/269811)
  * [GEE, ADRIAN](https://profiles.viictr.org/profile/268378)
  * [ROLLINS, LISA](https://profiles.viictr.org/profile/28998998)

[Explore](https://profiles.viictr.org/profile/269143/345)

_

Similar People (60)
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People who share similar concepts with this person.

  * [GOTTSCHALK, STEPHEN](https://profiles.viictr.org/profile/270181)
  * [ROONEY, CLIONA](https://profiles.viictr.org/profile/268355)
  * [SHPALL, ELIZABETH](https://profiles.viictr.org/profile/12582631)
  * [HESLOP, HELEN](https://profiles.viictr.org/profile/269811)
  * [BRENNER, MALCOLM](https://profiles.viictr.org/profile/268200)

[Explore](https://profiles.viictr.org/profile/269143/476)

_

Same Department [ ![Expand
Description](https://profiles.viictr.org/Framework/Images/info.png)
](JavaScript:toggleVisibility\('sdDescript'\);)

People who are also in this person's primary department.

  * [COOK, RICHARD G.](https://profiles.viictr.org/profile/266736)
  * [KNIGHT, JOHN](https://profiles.viictr.org/profile/18856558)
  * [KONDURI, VANAJA](https://profiles.viictr.org/profile/3009883)
  * [LEWIS, DOROTHY](https://profiles.viictr.org/profile/267982)
  * [ROSSEN, ROGER](https://profiles.viictr.org/profile/266540)

[Explore](https://profiles.viictr.org/search/default.aspx?searchtype=people&searchfor=&SearchRequest=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)

_

Physical Neighbors
![](https://profiles.viictr.org/profile/modules/passivelist/Images/info.png)

People whose addresses are nearby this person.

  * [COOK, RICHARD G.](https://profiles.viictr.org/profile/266736)
  * [KONDURI, VANAJA](https://profiles.viictr.org/profile/3009883)
  * [LAUCIRICA, RODOLFO](https://profiles.viictr.org/profile/266515)
  * [LEWIS, DOROTHY](https://profiles.viictr.org/profile/267982)
  * [ROSSEN, ROGER](https://profiles.viictr.org/profile/266540)

_

